Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 22Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 3Pancreatic Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2Colorectal Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Recurrence 1Pre-menopausal Breast Cancer 1Neoplasms 1Lung Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Gemcitabine 5Cisplatin 5Nivolumab 3Drug Therapy 3budigalimab 2Paclitaxel 2Injections 2Docetaxel 2Carboplatin 2zenocutuzumab 1venetoclax 1tislelizumab 1spartalizumab 1seribantumab 1saracatinib 1rovalpituzumab tesirine 1pertuzumab 1pemigatinib 1niraparib 1nilotinib 1margetuximab 1lenvatinib 1futibatinib 1fludarabine 1entrectinib 1durvalumab 1crenigacestat 1cediranib 1bemarituzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × NVP-BKM120 × Breast × Clear all
NCT01501604 2015-09-17

BKM120 in Cancers With PIK3CA Activating Mutations

Massachusetts General Hospital

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡